[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"The First Affiliated Hospital of Dalian Medical University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":180},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,42,67,99,129,153],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":4},"100588822","phase-4-two-different-regiments-of-pegmolesatide-for-anemia-in-patients-with-chronic-kidney-disease-not-receiving-dialysis-100588822",false,"NCT06946394","Two Different Regiments of Pegmolesatide for Anemia in Patients With Chronic Kidney Disease Not Receiving Dialysis","Application of Pegmolesatide in Renal Anemia: the Effectiveness and Safety of Switching to Two Different Regimens of Pegmolesatide in Patients With Non Dialysis CKD Treated With rhuEPO or HIF-PHI","Inclusion Criteria:\n\n1. Age ≥ 18 years old and ≤ 80 years old, gender not limited;\n2. Weight ≥ 45kg; Body Mass Index (BMI) ≥ 18.5kg\u002Fm\\^2;\n3. Diagnosed with CKD ≥ 6 months and estimated glomerular filtration rate (eGFR) ≥ 15mL\u002Fmin\u002F1.73m\\^2 before enrollment, and\\\u003C60 mL\u002Fmin\u002F1.73m\\^2 (estimated GFR using CKD-EPI formula), with no expected renal replacement therapy plan during the study period;\n4. rHuEPO or HIF-PHI should be used for ≥ 4 weeks and ≤ 12 weeks;\n5. During the 28days and 3days before randomization, with Hb ≥ 70g\u002FL and \\\u003C 110g\u002FL;\n6. Understand the research procedure and voluntarily sign an informed consent form (ICF) in writing.\n\nExclusion Criteria:\n\n1. Known to have hematological disorders or other diseases that cause anemia other than chronic kidney disease (CKD), such as primary pure red cell aplasia (PRCA), homozygous sickle cell disease, thalassemia\u002FCooley's anemia, multiple myeloma, hemolytic anemia, and myelodysplastic syndrome, or malignant tumors;\n2. Known to be allergic to iron agents or polyethylene glycol;\n3. Received red blood cell or whole blood transfusion therapy within the three months prior to randomization;\n4. Have received oral or intravenous immunosuppressive or glucocorticoid therapy within the 12 weeks prior to randomization;\n5. Individuals with poor blood pressure control;\n6. C-reactive protein ≥ 30mg\u002FL within the first 3 days of randomization;\n7. Pregnant and lactating women, women of childbearing age who have a positive urine β - HCG test result before the trial, or those who have a pregnancy plan during the study period;\n8. Assessment of cardiac function level III or IV within the first 3 days of randomization;\n9. Within the first 3 days of randomization, the liver function was assessed as Grade C;\n10. Researchers believe that subjects with any other factors that are not suitable for participating in this trial.","ALL","18 Years","80 Years",{"count":20,"type":21},160,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","This was a multicenter, randomized, open label, non inferiority clinical study. It consisted of a 24-week treatment period (0-24 weeks) and a 24-week extension period (25-48 weeks). About 160 patients which had received Recombinant human erythropoietin (rHuEPO) or Hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) treatment were randomized in a 1:1 ratio to receive Pegmolesatide with different administration regimens.",[27],"Renal Anemia in Non-dialysis Chronic Kidney Disease",[29],"Anemia","NOT_YET_RECRUITING","2025-04-23",{"date":33,"type":34},"2025-04-27","ACTUAL",{"date":36,"type":21},"2025-05",{"date":38,"type":21},"2026-11",{"name":40,"class":41},"The First Affiliated Hospital of Dalian Medical University","OTHER",{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":66},"100589254","pfa-based-bi-atrial-maze-like-catheter-ablation-for-peaf-100589254","NCT06952023","PFA-based Bi-atrial Maze-like Catheter Ablation for PeAF","Pulsed Field-Based Bi-atrial Maze-like Catheter Ablation Versus Pulmonary Vein Isolation in Persistent Atrial Fibrillation: A Multi-center Randomized Controlled Trial","PEACE-AF","Inclusion Criteria:\n\n* Patients diagnosed with symptomatic PeAF at 18-75 years old who are eligible for the PFA procedure, and have any the following documentation, within 180 days of randomization of either: i. A 24-hour continuous ECG recording (from any regulatory cleared rhythm monitoring device) confirming continuous AF, OR ii. Two ECGs (from any regulatory cleared rhythm monitoring device) showing continuous AF taken at least 7 days，OR iii. physician note of persistent continuous AF for \\> 7 days\n* The duration of AF lasting ≥ 1 year\n\nExclusion Criteria:\n\n* PaAF or PeAF with duration \\\u003C 1 year\n* has received catheter ablation procedure for AF or atrial septal defect repair before enrollment\n* left atrial diameter ≥55 mm or thrombosis in the left atrium\n* eGFR\\\u003C30mL\u002Fmin\u002F1.73m2\n* a history of cerebrovascular disease within the last three months (including stroke and transient ischemic attack)\n* acute or severe systemic infection\n* refused to participate in this trial; or those who have participated in other clinical drug trials within 3 months prior to enrollment\n* congenital heart disease, thyroid dysfunction, severe hepatic insufficiency (Child-Pugh classification B-C), severe coagulation dysfunction (international normalized ratio \\> 1.5 or partial activated prothrombin time prolonged by ≥ 10 seconds, or plasma prothrombin time prolonged by ≥ 3 seconds, or fibrinogen ≤ 1.5 g\u002FL), or active bleeding\n* pregnant women, breastfeeding women or women who plan to become pregnant during the study period, those who have a positive pregnancy test result during the screening period\n* life expectancy \\\u003C 12 months","75 Years",{"count":52,"type":21},390,[54],"NA","In radiofrequency (RF) ablation of persistent atrial fibrillation (PeAF), the additional linear ablation beyond pulmonary vein isolation (PVI) does not yield an reduce atrial arrhythmias recurrences.The goal of this clinical trial is to evaluate the efficiency of pulsed filed (PF) energy-based bi-atrial modified Maze ablation vs PF energy-based PVI of PeAF.\n\nThe main questions it aims to answer are:\n\nDoes PF energy effectively perform linear ablation in the left atrium? Does PFA-based bi-atrial modified Maze ablation significantly improve the success rate of PeAF ablation compared with PFA-based PVI?\n\nPatients with PeAF who meet the criteria and undergo catheter ablation will be randomly assigned to the study group (PF-based bi-atrial modified Maze ablation group) and control group (PF-based PVI only) in a 1:1 ratio. All patients will received a 7-d Holter at 3-,6-,9-,12-month after the ablation. The primary endpoint is the freedom from documented atrial arrhythmia (AF\u002FAFL\u002FAT lasting for over 30 seconds) recurrence monitored by ECG, 7-day ambulatory ECG, or equivalent cardiac monitoring from 4th to 12th month after the procedure without taking I\u002FIII AADs.",[57,58],"Atrial Fibrillation","Persistent Atrial Fibrillation",{"date":60,"type":34},"2025-04-30",{"date":62,"type":21},"2025-06",{"date":64,"type":21},"2027-10",{"name":40,"class":41},3,{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":74,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":75,"targetDuration":4,"studyType":77,"phases":4,"briefSummary":78,"conditions":79,"keywords":83,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},"100535362","benzodiazepine-impact-on-cognitive-function-fnirs-and-petmri-study-100535362","NCT06250842","Benzodiazepine Impact on Cognitive Function: fNIRs and PET\u002FMRI Study","Assessing the Cognitive Effects of Chronic Benzodiazepine Use in Patients: A Comprehensive Study Using fNIRs and PET\u002FMRI Technologies","Inclusion Criteria:\n\n1. Continuous use of benzodiazepines for ≥3 months, matched with participants who have not taken benzodiazepines.\n2. Education time ≥6 years.\n3. Abstained from alcohol, coffee, and other psychoactive substances in the 24 hours before the examination.\n\nExclusion Criteria：\n\n1. Brain damage due to various reasons (such as head trauma, dementia, epilepsy, brain tumors, etc.).\n2. Severe systemic diseases (such as malignant tumors, etc.).\n3. Acute cerebrovascular disease in the past 3 months. History of substance abuse other than benzodiazepines (such as alcohol, opioids, etc.).\n4. Inability to cooperate with fNIRS, PET\u002FMRI examinations, and scale assessments.",true,{"count":76,"type":21},100,"OBSERVATIONAL","This study explores the impact of long-term benzodiazepine (BZDs) use on cognitive function and associated neuroimaging markers. While BZDs are established treatments for conditions like anxiety and insomnia, recent warnings highlight risks, including neurocognitive effects. Neuroimaging studies indicate potential neuroprotective effects of BZDs. Functional near-infrared spectroscopy (fNIRS) measures cerebral cortex function during cognitive tasks. Combining fNIRS with mood and cognitive scales, this study assesses cortical activation. 2-deoxy-2-fluoro-D-glucose-positron emission tomography (FDG-PET) evaluates brain metabolism. DPA-714 PET assesses neuroinflammation. The primary objective is to compare brain functional activation, metabolism, and neuroinflammatory levels between long-term BZD users and non-users. This comprehensive approach aims to provide insights into BZD effects on cognition and associated brain markers.",[80,81,82],"Benzodiazepine Adverse Reaction","Depression, Anxiety","Benzodiazepine Dependence",[84,85,86,87,88],"Benzodiazepines","Long Term Adverse Effects","Cognitive Neuroscience","Neuroendocrinology","immunomodulatory potential","RECRUITING","2025-04-09",{"date":92,"type":34},"2025-04-11",{"date":94,"type":34},"2024-02-11",{"date":96,"type":21},"2027-06-30",{"name":40,"class":41},1,{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":50,"enrollmentInfo":107,"targetDuration":4,"studyType":22,"phases":109,"briefSummary":110,"conditions":111,"keywords":115,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":128},"100580415","deep-sedation-in-catheter-ablation-of-atrial-fibrillation-100580415","NCT06836999","Deep Sedation in Catheter Ablation of Atrial Fibrillation","Using Deep Sedation vs. Conscious Sedation in Catheter Ablation in Patients With Atrial Fibrillation: Intraprocedural Management and Outcome Evaluation","PRIORI-AF","Inclusion Criteria:\n\n● Patients diagnosed with AF (paroxysmal, persistent, or long-standing) at 18-75 years old who are eligible for the CA procedure\n\nExclusion Criteria:\n\n* has received CA procedure for AF or atrial septal defect repair before enrollment\n* left atrial diameter (LAD) ≥55 mm or thrombosis in the left atrium;\n* eGFR\\\u003C30mL\u002Fmin\u002F1.73㎡\n* a history of cerebrovascular disease within the last three months (including stroke and transient ischemic attack \\[TIA\\])\n* acute or severe systemic infection\n* intolerant to sedation or with a history suggestive of sleep apnea\n* BMI \\> 35 kg\u002F㎡\n* has contraindications to procedural sedation or refused to participate in this trial\n* Congenital heart disease, thyroid dysfunction, severe hepatic insufficiency (Child-Pugh classification B-C), severe coagulation dysfunction (international normalized ratio (INR) \\> 1.5 or partial activated prothrombin time (APTT) prolonged by ≥ 10 seconds, or plasma prothrombin time (PT) prolonged by ≥ 3 seconds, or fibrinogen (Fib) ≤ 1.5 g\u002FL), or active bleeding\n* pregnant women, breastfeeding women or women who plan to become pregnant during the study period, those who have a positive pregnancy test result during the screening period\n* life expectancy \\\u003C 12 months\n* those who have participated in other clinical drug trials within 3 months prior to enrollment\n* those who are known to be allergic to any of the ingredients such as lidocaine, propofol, soybeans, peanuts, etc.\n* those who, in the judgment of the investigator, are not suitable for this clinical study (e.g., not in line with the treatment that the research participants the treatment, research participant compliance, etc.).",{"count":108,"type":21},1334,[54],"The current practice of anesthesia for atrial fibrillation catheter ablation （CA） procedure is inconsistent, including general anesthesia, deep sedation, and conscious sedation.Due to the nature of deep sedation, it has been continuously gaining its position as one of the crucial components in standard practices of atrial fibrillation ablation during the last decade. Currently, a considerable number of procedures have been done using conscious sedation. Previous studies explored the benefits obtained from the employment of deep sedation in AF ablation procedures, mainly focused on pain reduction and intra-procedural safety. However, the benefits on long-term rhythmic outcomes, peri-procedural safety as well as benefits on procedural parameters and peri-procedural experiences from patients\u002Fablators\u002Flab staff have yet not to be thoroughly studied. We plan to conduct a prospective, multicenter, randomized, controlled trial to evaluate the benefits of deep sedation in catheter ablation of paroxysmal and persistent AF in multiple prospective, i.e., quantified intraprocedural patients \u002F physicians \u002F lab staffs \u002F mapper clinical specialist experiences, and the procedure safety.",[57,112,113,114],"Atrial Fibrillation, Paroxysmal or Persistent","Deep Sedations","Conscious Sedation",[116,117,118,119],"deep sedation","conscious sedation","catheter ablation","atrial fibrillation","2025-02-27",{"date":122,"type":34},"2025-03-04",{"date":124,"type":21},"2025-03-03",{"date":126,"type":21},"2027-12-31",{"name":40,"class":41},16,{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":135,"eligibilityCriteria":136,"healthyVolunteers":74,"sex":16,"minAge":137,"maxAge":138,"enrollmentInfo":139,"targetDuration":4,"studyType":22,"phases":141,"briefSummary":142,"conditions":143,"keywords":4,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":98},"100559577","dpa-714-and-fdg-petmri-in-depression-100559577","NCT06565936","DPA-714 and FDG PET\u002FMRI in Depression","Clinical Application of DPA-714 and FDG PET\u002FMRI Imaging in Patients With Depression","DAF-PMID","Inclusion Criteria:\n\n1. For all groups :\n\n   * No alcohol or psychoactive substances such as coffee had been consumed in the 24 hours prior to the examination\n   * MMSE≥24 points，MOCA≥26 points\n   * No anti-infective drugs in the past 1 month, no cold, fever or other infection history in the past 2 weeks\n   * Patients with diabetes had fasting controlled below 9.0mmol\u002FL before the examination\n   * Volunteer to participate in the study and sign the informed consent\n2. For Recurrent depression patients:\n\n   * Meet the Diagnostic criteria for recurrent major depressive disorder in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V)\n   * Age 35-85 years old, gender is not limited\n   * HAMD≥8 points\n3. For first episode depression Patients:\n\n   * Gender, age and education level were matched with the recurrent depression group\n   * Meet the Diagnostic criteria for the first episode of depressive disorder in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V)\n   * HAMD≥8 points\n4. For controls:\n\n   * Healthy people undergoing \"DPA-714 or FDG imaging PET\u002FMRI\" physical examination in PET\u002FCT room of our hospital\n   * Gender and education level were consistent with both the recurrent depression group and the first-episode depression group\n   * never used any psychotropic drugs\n   * HAMD\\\u003C8 points；HAMA\\\u003C7 points\n\nExclusion Criteria(for all groups):\n\n* Have a history of organic mental disorders or other mental disorders\n* A family history of hereditary diseases\n* Persons with mental retardation or dementia\n* A history of psychoactive substance abuse\n* Can not cooperate with\u002Fcomplete the psychological examination scale\n* Previously found serious physical diseases (heart, brain, liver, lung and kidney)\n* MRI contraindications, abnormalities found in head CT or MRI\n* A history of drug or alcohol abuse\n* Have a history of metabolic diseases such as hyperthyroidism, hypothyroidism,and rheumatic diseases\n* are in the state of pregnancy or breastfeeding","35 Years","85 Years",{"count":140,"type":21},70,[54],"Depression, a common psychological disorder, is characterized by persistent low mood, loss of interest, and anhedonia, leading to significant dysfunctions and a high suicide risk. Its pathogenesis remains challenging, with recent focus on neuroinflammation-a chronic immune response in the central nervous system-as a potential contributor. PET imaging, using tracers like 18F-FDG and \\[18F\\]DPA-714, can visualize metabolic and neuroinflammatory changes. Combining these two tracers can explore the correlation between neuroinflammation and glucose metabolism in depression, further elucidating its possible mechanisms. We hypothesize that microglial activation in depression, especially in major gray matter regions of interest (prefrontal cortex, anterior cingulate cortex, and insula) and 12 additional regions and subregions, will show higher TSPO levels and increased glucose metabolism compared to the control group.",[144],"Depression","2024-11-10",{"date":147,"type":34},"2024-11-12",{"date":149,"type":34},"2024-08-23",{"date":151,"type":21},"2026-12",{"name":40,"class":41},{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":4,"eligibilityCriteria":159,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":160,"enrollmentInfo":161,"targetDuration":4,"studyType":22,"phases":163,"briefSummary":164,"conditions":165,"keywords":167,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":179},"100382768","phase-4-huaiqihuang-granule-in-the-treatment-of-primary-glomerulonephritis-of-stage-ckd3-100382768","NCT04263922","Huaiqihuang Granule in the Treatment of Primary Glomerulonephritis of Stage CKD3","Huaiqihuang Granules in the Treatment of Primary Glomerulonephritis of Stage CKD3: a Randomized, Double-blind, Double-simulation, Positive Parallel Control Multi-center Clinical Study","Inclusion Criteria:\n\n1. Diagnosed as primary glomerulonephritis by renal biopsy\n2. Male or female, 18≤age≤65\n3. Blood pressure can be effectively controlled at or below 140\u002F90mmHg\n4. 30mL\u002F（min.1.73m2）≤ eGFR\\\u003C60mL\u002F（min.1.73m2）\n5. 24-hour urine protein ration ≤ 2.0g\u002F24h\n6. The participants must be capable of understanding and comply with the protocol and sign a written informed consent document\n\nExclusion Criteria:\n\n1. Diagnosed as secondary glomerulonephritis\n2. Exposure to corticosteroids, immunosuppressors, tripterygium glycosides, ARBs or ACEIs, without a two weeks washout period\n3. Blood pressure \\\u003C 90\u002F60 mmHg\n4. Serum potassium \\> 5.5 mmol\u002FL\n5. Serum albumin \\\u003C 30g\u002FL\n6. Unilateral or bilateral renal artery stenosis\n7. Pregnant or lactating women, and participants (including males) who were unable or unwilling to take adequate contraception during the study period\n8. Having comorbidities that affect the progression of primary glomerulonephritis (including but not limited to Malignant tumors, Systemic autoimmune diseases, Liver cirrhosis, Diabetes, and Gout)\n9. Allergic to the Huaiqihuang Granule or valsartan\n10. Participating in another clinical trial\n11. Investigators do not think it suitable for a participant to join this study","65 Years",{"count":162,"type":21},466,[24],"This is a multicentre prospective, randomized, double-blind and imitation, positive-drug parallel controlled clinical trail. The objective of this study is to evaluate the efficacy and safety of Huaiqihuang Granule in patients with CKD stage 3 primary glomerulonephritis.",[166],"Renal Insufficiency, Chronic",[168,169,170],"Primary Glomerulonephritis","Huaiqihuang Granule","CKD3","2024-07-10",{"date":173,"type":34},"2024-07-12",{"date":175,"type":34},"2020-06-30",{"date":177,"type":21},"2026-03-30",{"name":40,"class":41},34,""]